Micronutrients & recovery
Omega-3 fatty acid supplementation does not significantly alter ALT levels in individuals with MASLD.
Taking Omega-3 fatty acid supplements does not significantly lower liver enzymes (ALT) in people with MASLD compared to control groups. While Omega-3s are generally healthy, they should not be relied upon as a primary treatment for improving liver health biomarkers in this condition.
LCHF/ketogenic diets (n = 6) and Omega-3 fatty acids supplementation (n = 4) did not significantly alter ALT.
Why this rating
Meta-analysis of 4 RCTs, non-significant result.
Source
The impact of dietary interventions on liver health biomarkers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic literature review and meta-analysis of randomized controlled trials
Ute Stern et al. · European Journal of Nutrition · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →